Page 3 - Les Meilleurs Immunothérapie pour votre Immunothérapie - TOP 82 des médecins

Le Professeur Associé Tahsin Ozatli est spécialisé dans les cancers du sein, du poumon et gastro-intestinaux à l'Hôpital Universitaire Istinye Liv.

• Plus d'une décennie d'expérience en oncologie
• A travaillé à la Clinique d'Oncologie d'Ankara et à l'Hôpital Régional de Formation et de Recherche d'Erzurum
• Promu Professeur Associé en 2016
• A étudié la médecine à l'Université Selcuk

Médecin-chef au centre de cancérologie certifié du BKZ Solingen – Le Dr Fox est spécialisé en immunothérapie et en diagnostic moléculaire des maladies tumorales.

• Plus de 15 ans d'expérience en tant qu'hématologue, oncologue et immunologue
• Expert en recherche en biologie moléculaire pour les maladies hémato-oncologiques
• Membre de sociétés d'oncologie allemandes et américaines
• Spécialisé dans les thérapies ciblées parallèlement à l'immunothérapie

Le Dr Salman est spécialisé en immunothérapie pour divers cancers, intégrant des thérapies ciblées et des vaccins contre le cancer. Il a été formé dans des institutions prestigieuses comme le Memorial Sloan Kettering Cancer Center.

• Professeur agrégé à l'Université Katip Çelebi avec plus de 7 ans d'expérience en oncologie médicale
• Visiteur académique au Moffitt Cancer Center en Floride, États-Unis
• Membre du conseil d'administration de la Société Turque d'Oncologie Médicale et de la Société Européenne d'Oncologie Médicale
• Utilise un profilage génomique complet pour des plans de traitement personnalisés
• Actif dans la recherche clinique et les thérapies médicales expérimentales

Le Dr Alemdar est spécialisé en oncologie médicale et a suivi une formation approfondie à l'Université Akdeniz, un leader de la recherche sur le cancer.

• Certifié en oncologie médicale depuis 2018
• Exerce au Medical Park Antalya Hospital Complex
• Plus de 15 ans d'expérience en médecine interne et en oncologie
• Formé à l'Université Akdeniz – le premier centre de recherche sur le cancer en Turquie

Le Prof. Assoc. Nail Paksoy est spécialisé en immunothérapie à l'Hôpital Medipol Bahçelievler, avec une solide expérience en oncologie médicale et en allergologie-immunologie.

• Certifié par l'ESMO en oncologie médicale
• A participé à 8 essais cliniques internationaux pour l'immunothérapie
• A publié de multiples études sur les résultats du traitement du cancer
• Formation de bourse (Fellowship) à l'Institut d'oncologie de l'Université d'Istanbul

Le Dr Ozden est spécialisé en oncologie médicale et possède plus de 20 ans d'expérience en médecine interne et en oncologie.

• A complété sa surspécialité en oncologie médicale à la Faculté de Médecine de l'Université de Kocaeli
• A exercé la médecine interne dans plusieurs hôpitaux en Turquie
• Est diplômé de la Faculté de Médecine Cerrahpaşa de l'Université d'Istanbul

Professeur d'Oncologie Médicale avec plus de 20 ans d'expérience, spécialisé dans les traitements avancés contre le cancer à l'Hôpital Liv Topkapı de l'Université İstinye.

• Formation de spécialisation (Fellowship) en Oncologie Médicale à l'Université de Trakya
• Professeur agrégé puis Professeur à la Faculté de Médecine de l'Université de Trakya
• Membre de l'Association Turque d'Oncologie Médicale

Le Professeur Associé Atakan Topcu est spécialisé en immunothérapie et en thérapies ciblées pour les tumeurs solides à l'Hôpital de District Medipol Acibadem.

• A publié plus de 50 articles scientifiques en oncologie
• Membre de la Société Européenne d'Oncologie Médicale (ESMO)
• Expert en oncologie gériatrique et en malnutrition liée au cancer
• Titulaire d'un fellowship en oncologie médicale, formé à l'Université Bezmialem Vakıf

Le Dr Eckhart Weidmann dirige le secteur d'Hématologie à la Clinique Nordwest. Il est spécialisé dans le traitement des maladies du sang et cumule plus de 30 ans d'expérience clinique.

• L'un des meilleurs médecins pour le lymphome non hodgkinien
• Professeur possédant une expertise académique et clinique approfondie
• Se concentre sur l'immunothérapie pour les maladies du sang

Professeur Associé d'Oncologie Médicale à l'Hôpital Liv de l'Université İstinye Topkapı – spécialisé dans l'immunothérapie pour le traitement du cancer.

• Plus de 10 ans d'expérience en oncologie médicale
• Membre de l'American Society of Clinical Oncology (ASCO)
• A publié plusieurs articles évalués par des pairs sur les résultats des traitements oncologiques
• Se concentre sur l'immunothérapie pour divers types de cancer

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.

She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.

She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Chef de file de renommée mondiale dans le domaine de la Leucémie Lymphoïde Chronique (LLC) – Le Professeur Bosch dirige plus de 80 essais cliniques sur de nouveaux traitements.

• Spécialisé dans les lymphomes et la LLC, avec des approches thérapeutiques innovantes
• Chef du service d'Hématologie à l'Institut d'Oncologie IOB
• A publié plus de 100 articles dans des revues de premier plan telles que NEJM et Nature Medicine
• Professeur d'Hématologie à l'Hôpital Universitaire Vall d'Hebron